NASDAQ:XON - Intrexon Stock Price, Forecast & News

Intrexon trades on the NASDAQ under the ticker symbol "XON."

Intrexon Corp (NASDAQ:XON) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. The biotechnology company earned $23.04 million during the quarter, compared to analyst estimates of $32.16 million. Intrexon had a negative net margin of 393.13% and a negative return on equity of 45.51%. View Intrexon's Earnings History.

Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intrexon.

3 analysts have issued 1-year target prices for Intrexon's shares. Their forecasts range from $6.00 to $43.00. On average, they expect Intrexon's stock price to reach $19.67 in the next twelve months. This suggests a possible upside of 268.3% from the stock's current price. View Analyst Price Targets for Intrexon.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.

Media coverage about XON stock has trended negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intrexon earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Intrexon.

Some companies that are related to Intrexon include Medpace (MEDP), National Research (NRC), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Eloxx Pharmaceuticals (ELOX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI) and Tenax Therapeutics (TENX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and General Electric (GE).

Intrexon's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.14%), California Public Employees Retirement System (0.08%), Alpine Global Management LLC (0.05%), Janney Montgomery Scott LLC (0.03%) and Addison Capital Co (0.01%). Company insiders that own Intrexon stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon.

XON stock was sold by a variety of institutional investors in the last quarter, including Addison Capital Co and Janney Montgomery Scott LLC. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon.

XON stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, California Public Employees Retirement System and Sanders Morris Harris LLC. View Insider Buying and Selling for Intrexon.

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XON stock can currently be purchased for approximately $5.34.

Intrexon has a market capitalization of $868.71 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon.

The official website for Intrexon is http://www.dna.com/.

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]